We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Insertable Cardiac Monitor with World's Longest Battery Life to Aid Long-Term Monitoring of Heart Rhythms

By HospiMedica International staff writers
Posted on 22 May 2023
Print article
Image: Assert-IQ ICM is the world’s longest lasting Bluetooth-enabled insertable cardiac monitor (Photo courtesy of Abbott)
Image: Assert-IQ ICM is the world’s longest lasting Bluetooth-enabled insertable cardiac monitor (Photo courtesy of Abbott)

Arrhythmias, or irregular heartbeats, can be very random, complicating diagnoses for many patients. Insertable cardiac monitors (ICMs) – small devices with sensors that are inserted just beneath the chest's skin – aim to facilitate consistent, real-time heart monitoring to detect and identify arrhythmias that can trigger symptoms such as fainting, an irregular pulse, and shortness of breath. Now, an ICM boasting the world’s longest battery life offers long-term monitoring and remote programming to enhance patient connectivity. The device delivers constant monitoring for abnormal heart rhythms and includes features intended to enhance data management and workflow within a physician's practice.

Most commercially available ICMs monitor an individual's heart rhythms for a couple of years, but Assert-IQ from Abbott (Abbott Park, IL, USA) presents two options with a minimum battery life of either three or six years, offering doctors a new level of flexibility in diagnostic monitoring. While the three-year option might be more suitable for traditional monitoring, such as diagnosing fainting, heart palpitations or detections of abnormal heart rhythms, the six-year battery life option allows physicians to monitor patients over an extended period. This longer-term monitoring can be crucial for individuals undergoing therapy, those who have recently undergone a cardiac ablation procedure, or those at risk of developing further arrhythmias like atrial fibrillation. Both options feature advanced algorithms to detect irregular heartbeats and provide clinically actionable data.

With the integration of Bluetooth technology, Abbott's Assert-IQ ICM is designed to stay connected to a transmitter – typically the patient's own cell phone – where it checks heart rhythms every 20 seconds, transmitting results in real-time to the clinic's portal. Furthermore, some Assert-IQ ICM models can be remotely programmed, allowing clinicians to tweak the device's settings, optimize performance, and reduce unnecessary alerts or transmissions – all without necessitating the patient's clinic visit. The Assert-IQ ICM also offers advanced diagnostic capabilities to furnish physicians with more clinically pertinent information about the patient's cardiovascular health, enabling healthcare providers to make faster clinical decisions. Abbott has secured clearance from the U.S. Food and Drug Administration (FDA) for its Assert-IQ ICM, providing physicians with a new alternative for diagnostic evaluation and long-term monitoring of individuals experiencing irregular heartbeats.

"As the incidence of abnormal heart rhythms like atrial fibrillation continue to rise, more doctors are turning to ICM technology to monitor their patients remotely to better detect the cause of symptoms that can impact overall health and quality of life," said Leonard Ganz, M.D., divisional vice president of medical affairs and chief medical officer of Abbott's cardiac rhythm management business. "Until now, insertable cardiac monitors have allowed for remote monitoring of patients but lacked the longevity needed to monitor them long-term. Abbott's Assert-IQ ICM offers physicians a connected health device that will help them provide the best care for their patients while making more accurate and informed treatment decisions."

Related Links:
Abbott

Gold Supplier
12-Channel ECG
CM1200B
New
Multi-Parameter Patient Monitor
S80
New
Oxygen Therapy Hyperbaric Chamber
Sechrist 2800
New
Lesion Tracking Application
Sectra Lesion Tracking

Print article
FIME - Informa

Channels

AI

view channel
Image: The AI tool can also tackle dangerous inequalities in heart attack diagnosis (Photo courtesy of Freepik)

AI Algorithm Integrates Cardiac Troponin Test Results with Clinical Data to Quickly Rule out Heart Attacks in Patients

The accepted standard for diagnosing myocardial infarction, or heart attack, involves assessing the blood for troponin levels. However, this approach applies the same benchmark for all patients, failing... Read more

Surgical Techniques

view channel
Image: The deployable electrodes are ideal for minimally invasive craniosurgery (Photo courtesy of EPFL)

Soft Robotic Electrode Offers Minimally Invasive Solution for Craniosurgery

Minimally invasive medical procedures offer numerous benefits to patients, including decreased tissue damage and shorter recovery periods. However, creating equipment that can pass through a small opening... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: IntelliSep is the first FDA-cleared diagnostic tool to assess cellular host response to aid in identifying ED patients with sepsis (Photo courtesy of Cytovale)

Rapid Microfluidic Test Demonstrates Efficacy as Diagnostic Aid to Improve Sepsis Triage in ED

Sepsis is the primary cause of mortality worldwide, accounting for over 350,000 fatalities annually in the United States alone, a figure that surpasses deaths from opioid overdoses, prostate cancer, and... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.